We Think That There Are More Issues For Sino BiologicalInc (SZSE:301047) Than Just Sluggish Earnings
We Think That There Are More Issues For Sino BiologicalInc (SZSE:301047) Than Just Sluggish Earnings
Sino Biological,Inc.'s (SZSE:301047) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying factors which may be of concern.
Sino Biological,Inc. (SZSE:301047) 最近發佈的疲弱業績並未引起股票大幅波動。然而,我們認爲投資者應該注意一些潛在的可能令人擔憂的因素。

How Do Unusual Items Influence Profit?
非常規項目如何影響利潤?
To properly understand Sino BiologicalInc's profit results, we need to consider the CN¥20m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Sino BiologicalInc had a rather significant contribution from unusual items relative to its profit to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
爲了充分了解Sino BiologicalInc的盈利結果,我們需要考慮到飛凡事項所貢獻的2,000萬人民幣收益。我們不得不承認,更高的盈利通常讓我們樂觀,但我們更希望盈利能夠持續。當我們分析全球大多數上市公司時,我們發現重要的飛凡事項通常不會重複出現。這並不奇怪,鑑於其名稱。與2024年9月相比,Sino BiologicalInc相對於其利潤有相當大比例來自飛凡事項。其他條件相同的情況下,這可能會導致法定利潤成爲衡量基礎盈利能力的不良指標。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。
Our Take On Sino BiologicalInc's Profit Performance
我們對Sino BiologicalInc的盈利表現的看法
As we discussed above, we think the significant positive unusual item makes Sino BiologicalInc's earnings a poor guide to its underlying profitability. For this reason, we think that Sino BiologicalInc's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For instance, we've identified 2 warning signs for Sino BiologicalInc (1 is concerning) you should be familiar with.
正如我們上面討論的那樣,我們認爲重大的正向飛凡項目使得Sino BiologicalInc的盈利成爲其潛在盈利能力的不良指引。因此,我們認爲Sino BiologicalInc的法定利潤可能是其潛在盈利能力的糟糕指引,並可能給投資者對該公司過於積極的印象。遺憾的是,其每股收益在過去十二個月下降了。當然,在分析其盈利方面我們只是觸及了皮毛;人們也可以考慮利潤率、預測增長、投資回報等其他因素。因此,如果您想深入了解這支股票,考慮到它所面臨的任何風險是至關重要的。例如,我們已經爲Sino BiologicalInc確定了2個警示信號(其中1個令人擔憂),您應該熟悉。
Today we've zoomed in on a single data point to better understand the nature of Sino BiologicalInc's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天我們聚焦在一個數據點上,以更好地了解Sino BiologicalInc盈利的性質。但如果您能夠專注心思到細微之處,總是有更多發現的。例如,許多人認爲高股本回報率是有利的商業經濟指標,而另一些人則喜歡「跟着錢走」,尋找內部人員正在購買的股票。雖然您可能需要進行一些研究,但您可能會發現這個收集了高股本回報率公司的免費資料,或者這份具有重要內部持股的股票清單是有用的。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。